Daily Big Picture – Nifty Retakes its 200-DMA; Lupin Gets a EU nod for NaMuscla Drug

Today’s Action

Benchmark indices ended in the green today. Nifty, +0.3%, Sensex, +0.4%, Model Portfolio, -0.2%; MSI Ind 47, -0.02%, Nifty Midcap -0.1%, Smallcap +0.3%.

Daily Market Review

Market Status: Uptrend Under Pressure

India’s benchmark indices continued to post gains for the third straight session taking cues from global indices.

Nifty PSU bank (+2.8%), Pharma (+1.5%) helped the market to post gains, while Media (-1.2%) tried to drag the market down. Nifty Pharma was led by Sun Pharm.Industries (+4.0%) whereas Nifty Bank was led by Icici Bank (+3.4%) and State Bank Of India (+3.0%) stocks. Zee Entertainment Ents. (-2.4%) and Upl (-1.5%) were the major losers among Nifty50 stocks.

The advance-decline ratio was slightly in favor of decliners. Of the 2,066 stocks traded on the NSE, 829 advanced, 896 declined, and 341 remained unchanged.

Stocks in News

Himachal Futr.Comms.: The Company’s board approved adding a new manufacturing facility at Hyderabad. With this addition, manufacturing capacity of optical fibre cable will expand to 10.5 mn fibre kilometre (FKM) from the existing 7 mn FKM. The stock rose 12.2% today.

Lupin: The Company received nod from EU for a drug NaMuscla, which is used to treat a rare neuromuscular disorder. It also received the FDA approval for Lurasidone Hydrochloride tablets. The stock was up 2.4% today.

Leaders Up on Volume: Iol Chemicals & Pharms. (+8.3%) and Praj Industries (+5.7%)

Leaders Down on Volume: Havell’s India (-3.4%) and Godrej Consumer Products (-2.6%)

To Read Detailed Reports including Stock Recommendations, Idea Lists, Evaluate Stocks etc. Subscribe to  MarketSmith India.